DIRS.INFO The most relevant business & tech news

☆ Earnings playbook: Your guide to trading another busy week of reports, including Apple and Pfizer
▼ + stars: | 2023-10-29 | by ( Fred Imbert | ) www.cnbc.com time to read: +6 min

About 30% of the S & P 500 is set to report earnings this week, bringing the reporting past the halfway mark. Monday McDonald's is set to report earnings before the bell, followed by a call with management at 8:30 a.m. What CNBC is watching: Pfizer is coming into this latest earnings report limping. What history shows: Starbucks only beats earnings expectations 55% of the time, according to Bespoke, but the stock averages a 0.5% gain on earnings days. What history shows: Apple shares tend to do well on earnings days, averaging a 1.3% advance, according to Bespoke.

Persons: It's, Oppenheimer, Brian Bittner, PFE, Kif Leswing, Cowen, Andrew Charles, bode, Tim Cook, — CNBC's Michael Bloom Organizations: Apple, Pfizer, Meta, CNBC, Investment, AMD, Nvidia, Starbucks, Corporate Locations: U.S, Covid, China

☆ Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end
▼ + stars: | 2023-10-29 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +11 min

Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don't expect this duopoly to end soon, analysts say. All this goes on amid robust demand for Novo's semaglutide, which is sold as Ozempic for type 2 diabetes and as Wegovy for weight loss, and Lilly's tirzepatide, which hopes to receive regulatory approval for weight loss this year. Orforglipron is an oral drug Eli Lilly is developing. It has several other compounds in the pipeline, but Suvannavejh expects the weight loss drug to receive increased attention. "This range would also be competitive with LLY's orforglipron [an oral GLP-1 drug] weight loss at day 28," Smith said.

Persons: Eli Lilly, Piper Sandler, Yasmeen Rahimi, Cantor Fitzgerald, Louise Chen, Lilly, Lilly's, Chen, Price, Kyle Rasbach, We've, Rasbach, Altimmune Altimmune, NASH, Piper's, Rahimi, Cantor's Chen, it's, Eli Lilly's Mounjaro, Goldman Sachs, Chris Shibutani, David Risinger, Risinger, Jonathan Wolleben, Wolleben, Orforglipron, Graig Suvannavejh, Suvannavejh, Thomas Smith, LLY's, Smith, Yale Jen, Jen Organizations: Novo Nordisk, Pfizer, Novo, pharma, Pfizer Pfizer, danuglipron, Therapeutics, Leerink, Mizuho Securities, Viking Therapeutics Viking Therapeutics, Laidlaw & Co Locations: Novo, GLP, Eventide

☆ Jamie Dimon's stock-moving trades show why investors should track CEOs' buying and selling
▼ + stars: | 2023-10-28 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +24 min

While executive stock sales — such as Dimon's planned transactions next year — are not universally red flags, they can get complicated. Insider stock sales Executive stock trades are usually disclosed through SEC filings known as Form 4 documents and accessible through the regulator's EDGAR database — the electronic data gathering, analysis, and retrieval system. Rule 10b5-1 trading plans came into the fold just over two decades ago to reconcile these two discordant facts. Adopting Rule 10b5-1 trading plans gives public-company executives a way to protect against allegations of illegal insider trading in the future. Compared with a tiny stock sale executed through a predetermined plan, executive stock buys generally send a much stronger signal: The executive wants to make money, too.

Persons: Jamie Dimon, Dimon, Jim Cramer, Jim, Eliezer Fich, Dimon's, EDGAR, Chester Spatt, Spatt, —, Susan Li, Drexel's, Wharton, Drexel's Fich, Fich, I'm, Nancy Quan's, Quan, Marc Benioff, Carnegie Mellon's Spatt, Benioff, Howard Schultz, Schultz's, Schultz, Carnegie Mellon's, Nikesh Arora, Arora, Charles Scharf, Wells, Sehwa Kim, Kim, Foot, Mary Dillon, Locker, Dillon, Foot Locker, Jim Cramer's, Al Drago Organizations: JPMorgan Chase, JPMorgan, Dow Jones Industrial, Wall, Dimon, Pfizer, Capitol, Drexel University, Club, Securities, Exchange Commission, SEC, Carnegie Mellon's Tepper School of Business, CNBC, Stanford University, University of Pennsylvania's Wharton School, Stanford, Cola, Salesforce, Carnegie, Starbucks, Palo Alto Networks, Alto Networks, Broadcom, Federal Reserve, Washington Service, Columbia Business School, JPMorgan Chase &, Bloomberg, Getty Locations: U.S, Coke, Salesforce, FL

☆ Jobs and earnings are major themes next week as we consider more portfolio moves
▼ + stars: | 2023-10-28 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

But in the end, it's fundamentals that drive earnings and earnings that drive stock prices. Looking ahead to next week, we'll get several important macroeconomic updates along with nine Club earnings reports. Economic releases Next week is Jobs Friday when we get the government's monthly nonfarm payrolls report. Club stock earnings Club name Caterpillar (CAT) reports third-quarter results before the opening bell Tuesday. DuPont (DD) is set to report earnings.

Persons: it's, we'll, nonfarm payrolls, We'll, Estee Lauder, Eli Lilly, BUD, Jerome Powell, Kraft Heinz, WEN, Papa John's, Dwight Co, Jim Cramer's, Jim Cramer, Jim, Brendan Mcdermid Organizations: Caterpillar, GE Healthcare, DuPont, Bausch Health, Starbucks, Apple Watch, VF Corp, GE HealthCare, Pfizer, JetBlue, Anheuser, Busch InBev, Devices, Caesars Entertainment, Cruise, CVS Health, Brinker International, Yum Brands, PayPal, Qualcomm, Mondelez, Novo Nordisk, Barrick, Penn Entertainment, Paramount Global, Marriott, Ferrari, Molson Coors, TAP, Coinbase, Natural Resources, Booking Holdings, International, Monster Beverage, Health, Resources, Dwight, Restaurant Brands, Sempra Energy, Jim Cramer's Charitable, CNBC, Traders, New York Stock Exchange Locations: North America, China, New York City, U.S

☆ Sanofi loses $21 bln in market value after dropping 2025 profit target
▼ + stars: | 2023-10-27 | by ( Ludwig Burger | ) www.reuters.com time to read: +6 min

Under a push to spend more on immunology and inflammation drug development, the company abandoned a target for a 32% operating profit margin for 2025 to focus on "long-term profitability". EPS would see a strong rebound in 2025 but not enough to sustain the previous margin target. CONSUMER STAND-ALONECEO Hudson said the core innovative drugs business had improved enough to soon do without the more predictable cash flows from consumer products. The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. The timing of the potential consumer listing, which Sanofi said would be in the fourth quarter of 2024 or later, would be set to maximize shareholder value.

Persons: Hudson, Sanofi, drugmaker, Paul Hudson, Terence McManus, Johnson, we've, Gonzalo Fuentes, Roche, Dupixent, Ludwig Burger, Sherry Jacob, Phillips, Mark Potter, Sharon Singleton Organizations: Sanofi, Bellevue Asset Management, Reuters, Barclays, Johnson, GSK, Pfizer, Bayer, Polyclonals, REUTERS, Provention, Merck & Co, Thomson Locations: France, Bellevue, Lyon, Paris

The government has been overseeing distribution of the treatments, alongside vaccines and tests, but has transferring that work to traditional commercial channels. Commercial ordering for the treatments is set to start on Nov. 1. Returns will begin on Nov. 15, the official said, and will be accepted through the end of the year. The government is recommending returns start in December enough time for the establishment of patient assistance programs and securing of commercially-labeled doses. Reporting by Ahmed Aboulenein Editing by Marguerita ChoyOur Standards: The Thomson Reuters Trust Principles.

Persons: Lagevrio, Ahmed Aboulenein, Marguerita Choy Organizations: U.S, Pfizer, Paxlovid, U.S . Department of Health, Human Services, Thomson Locations: U.S

☆ Merck quarterly profit tops expectations on COVID pill surprise
▼ + stars: | 2023-10-26 | by ( Michael Erman | ) www.reuters.com time to read: +2 min

The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. Merck raised Lagevrio full-year sales forecast to $1.3 billion. Third-quarter sales of Merck's top-selling cancer immunotherapy, Keytruda, stood at $6.34 billion, surpassing analysts' average estimate of $6.22 billion. Gardasil, its vaccine to prevent cancers caused by human papillomavirus (HPV), generated sales of $2.59 billion, rising 13% but missing analysts' average estimate of $2.69 billion. The company posted sales of $15.96 billion in the reported quarter, compared to the average analyst estimate of $15.3 billion.

Persons: Brendan McDermid, Molnupiravir, Merck, Wells, Mohit Bansal, drugmaker, Michael Erman, Leroy Leo, Bill Berkrot Organizations: Merck, Co, REUTERS, Merck & Co, Pfizer's, Thomson Locations: Rahway , New Jersey, U.S, Japan, United States, EU

☆ Roche's $7 bln deal is pricey and partial cure
▼ + stars: | 2023-10-23 | by ( ) www.reuters.com time to read: +2 min

Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustration shot January 22, 2016. REUTERS/Dado Ruvic/Illustration Acquire Licensing RightsNEW YORK, Oct 23 (Reuters Breakingviews) - Roche (ROG.S) has taken a small step towards curing its drug pipeline problem. JPMorgan analysts estimate that the drug’s U.S. sales could peak at 2.4 billion Swiss francs ($2.7 billion), but will take until 2037 to get there, assuming a 2028 launch. Analysts expect Roche’s pharmaceutical division to generate revenue of almost 45 billion Swiss francs this year, according to estimates compiled by LSEG. With expected free cash flow of around 16 billion Swiss francs this year and next, Roche can afford to buy a little more diversification.

Persons: Roche, Dado Ruvic, Thomas Schinecker, Peter Thal Larsen, Jean, Pierre Mustier, Atos, Jonathan Guilford, Aditya Sriwatsav Organizations: REUTERS, Reuters, Pfizer, U.S, New, JPMorgan, Merck, Prometheus Biosciences, Analysts, LSEG, X, News Corp, Thomson Locations: Swiss, U.S

New Roche CEO Thomas Schinecker is keen to restore Roche's battered drug development record after major late-stage trial setbacks in the areas of Alzheimer's and cancer immunotherapy last year. The acquired drug, against inflammatory bowel disease such as ulcerative colitis and Crohn's disease, belongs to a class of new treatments known as anti-TL1A antibodies which has attracted major deal activity in the pharma industry. Merck & Co (MRK.N) in April agreed to buy anti-TL1A antibody developer Prometheus Biosciences for $10.8 billion. Inflammatory bowel disease is a group of chronic gastrointestinal disorders with almost 8 million people diagnosed worldwide and 80% of all individuals not experiencing lasting remission, Roche said. "We strongly believe this novel TL1A directed antibody has the transformational potential to make a significant difference for patients living with inflammatory bowel disease and potentially other diseases," said Roche CEO Schinecker.

Persons: drugmaker Roche, Arnd, New Roche, Thomas Schinecker, Schinecker, Roche, John Revill, Ludwig Burger, Friederike Heine, Jason Neely Organizations: REUTERS, Roivant Holdings, Pfizer Inc, pharma, Sanofi, Merck & Co, Prometheus Biosciences, Thomson Locations: Basel, Switzerland, ZURICH, FRANKFURT, Swiss, U.S, Japan, Zurich, Frankfurt

☆ Stocks like Nvidia have 'earnings upside' ahead of quarterly reports, Wall Street analysts say
▼ + stars: | 2023-10-21 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Earnings season is in full swing, and Wall Street analysts named a slew of well-positioned stocks heading into quarterly results. CNBC Pro combed through recent Wall Street research to find stocks with earnings upside. They include Nvidia, Dover, Arista Networks , Xcel Energy, Pfizer and Costco. Analyst Amit Daryanani and his team added a tactical outperform to the stock ahead of earnings on Oct. 30. … We continue to see multiple paths to double digit growth for Arista in 2024 and their analyst day should confirm this outlook."

Persons: Oppenheimer, Bryan Blair, Blair, Dover's, Murphy, Dover, Amit Daryanani, Daryanani, Julien Dumoulin, Smith, Xcel, XEL, Dover – Oppenheimer, DOV, William Blair, Pfizer – Cantor Fitzgerald, PFE, …, Nvidia – Jefferies Organizations: Wall Street, CNBC, Nvidia, Arista Networks, Xcel Energy, Pfizer, Costco, Dover, ISI, Arista, Xcel Energy Bank of America, Energy – Bank of America, …, … Arista, Automotive, & $ Locations: Dover

☆ Merck’s cancer rush may spawn lower returns
▼ + stars: | 2023-10-20 | by ( ) www.reuters.com time to read: +2 min

The American drug company said on Thursday it signed a giant deal with Daiichi Sankyo (4568.T) for the rights to sell three potential drugs outside Japan. Merck will pay $4 billion upfront, up to another $1.5 billion over the next two years, and as much as $16.5 billion if the drugs pass certain sales milestones. Merck’s Keytruda accounts for about 40% of the company’s revenue, and that cancer drug might face cut-price competition before the end of the decade. The potential is giant, as these targeted therapies might eventually account for a quarter of the current oncology market. With over 100 of these drugs in clinical trials, the stampede might lead to lower-than-expected returns.

Persons: Jeff Zelevansky, Robert Cyran, Jean, Pierre Mustier, Atos, Jennifer Saba, Aditya Sriwatsav Organizations: Merck & Co, REUTERS, Reuters, Merck, Pfizer, X, News Corp, Thomson Locations: Linden , New Jersey, American, Japan

Companies Pfizer Inc FollowSeagen Inc FollowBRUSSELS, Oct 19 (Reuters) - U.S. pharmaceutical company Pfizer (PFE.N) gained unconditional EU antitrust approval on Thursday for its proposed $43 billion acquisition of cancer drug maker Seagen (SGEN.O). Pfizer announced the deal in March, its largest purchase in a string of recent acquisitions thanks to a once-in-a-lifetime cash windfall from its COVID-19 vaccine and treatment. The European Commission said the deal would not significantly reduce competition in the 27-country European Union nor would it have a negative impact on prices. "The proposed merger would not raise competition concerns," the EU antitrust watchdog said in a statement. Washington-based Seagen is a pioneer of antibody-drug conjugates, which work like "guided missiles" designed to destroy cancer while sparing healthy cells.

Persons: Foo Yun Chee Organizations: Pfizer, European Commission, Thomson Locations: Union, Washington

☆ Pfizer to price COVID treatment Paxlovid at $1,390 per course
▼ + stars: | 2023-10-18 | by ( Michael Erman | ) www.reuters.com time to read: +3 min

The new list price, which does not include rebates and other discounts to insurers and pharmacy benefit managers, is $1,390 per course, Pfizer said in an emailed statement. The U.S. government paid around $530 per course for Paxlovid it has made available to Americans at no cost. The United States purchased around 24 million courses of the oral two-drug treatment from Pfizer, and still had a large supply, but arranged to return 7.9 million courses last week. In 2022, patients were given around 7 million courses of the drug, according to U.S. government data. Through Oct. 1, around 3.4 million courses had been administered in 2023.

Persons: Wolfgang Rattay, Paxlovid, Michael Erman, Bill Berkrot Organizations: REUTERS, Pfizer, for Clinical, Economic, United, Wall Street, Thomson Locations: U.S, United States, Maplewood , N.J

☆ Pfizer, BioNTech shares fall on lower COVID product sales forecast
▼ + stars: | 2023-10-16 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

REUTERS/Dado Ruvic/File photo Acquire Licensing RightsOct 16 (Reuters) - Shares of Pfizer (PFE.N) and German partner BioNTech (22UAy.DE) fell on Monday after the U.S. drugmaker slashed the sales forecast for its COVID vaccine and therapy last week, and some analysts said the reduction was bigger than expectations. The COVID sales forecast cut was bigger than expected, Wells Fargo analyst Mohit Bansal said, adding that Wall Street's COVID sales estimates for the next few years may come down. Shares in BioNTech, which is also developing cancer treatments, were down 6.7% at a two-month low in Frankfurt. Its U.S.-listed shares fell 6.8% in premarket trading, while Pfizer's shares fell 2%. The news also dragged down shares of rival COVID vaccine maker Moderna (MRNA.O) by 4.7%.

Persons: Dado, BioNTech, drugmaker, Wells, Mohit Bansal, Ludwig Burger, Rachel More, Miranda Murray, Jason Neely, Shounak Organizations: COVID, Institute for Health, Food, REUTERS, Pfizer, U.S, Its U.S, Moderna, Manas Mishra, Thomson Locations: Zenica, Bosnia, Herzegovina, Wells Fargo, BioNTech, Frankfurt, Its, Bengaluru

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 28, 2023. The S&P 500 and the Nasdaq dropped on Friday as deteriorating consumer sentiment data and the Middle East conflict kept investors away from riskier bets and overshadowed some upbeat earnings from big U.S. banks. Third-quarter earnings for the S&P 500 companies are estimated to grow 2.2% on an annual basis, LSEG data showed. Of the 32 S&P 500 companies that have reported results, 87.5% have surpassed expectations compared with the long-term average of 66.5%. Rival Moderna (MRNA.O) dipped 5.1%Lululemon Athletica (LULU.O) added 5.8% as the sportswear apparel maker is set to join the S&P 500 index this week, replacing Activision Blizzard (ATVI.O).

Persons: Brendan McDermid, Antony Blinken, Pissouros, Goldman Sachs, Morgan Stanley, Johnson, Charles Schwab, Patrick Harker, Jerome Powell, Harker, Austan Goolsbee, Ankika Biswas, Shashwat Chauhan, Arun Koyyur, Vinay Dwivedi Organizations: New York Stock Exchange, REUTERS, Reuters, Pfizer, Dow, Nasdaq, Treasury, XM, Bank of America, Johnson, Tesla, Netflix, Philly, New York, Philadelphia Fed, Federal, Chicago Fed, Dow e, Nvidia, Activision Blizzard, Thomson Locations: New York City, U.S, China, Israel, Gaza, United States, Bengaluru

Vaccine makers are depending on the U.S. market as many countries have more limited yearly campaigns for giving updated shots. For BioNTech, Moderna, and Novavax (NVAX.O), COVID vaccines remain their only approved products. Shares of Pfizer were up nearly 5%, however, buoyed by a $3.5 billion cost-cutting plan the drugmaker announced late on Friday alongside its new COVID sales outlook. Moderna, in a statement on Monday, maintained its current revenue forecast of $6 billion to $8 billion for its COVID vaccine for 2023. Jefferies analyst Michael Yee said Pfizer's new COVID outlook implies lower vaccine sales for Moderna than it had forecast.

Persons: Dado, BioNTech, Albert Bourla, Bourla, Mani Foroohar, Foroohar, Jefferies, Michael Yee, Ludwig Burger, Rachel More, Michael Erman, Bhanvi Satija, Manas, Jonathan Oatis, Caroline Humer, Bill Berkrot Organizations: COVID, Institute for Health, Food, REUTERS, Pfizer, Moderna, Manas Mishra, Thomson Locations: Zenica, Bosnia, Herzegovina, Frankfurt, Novavax, U.S, New York, Bengaluru

☆ Pfizer gets upgrade at Jefferies, which says there's a buying opportunity in the pharma giant's stock
▼ + stars: | 2023-10-16 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

Jefferies thinks its time for investors to go long on Pfizer . "In our view, PFE has one of the most intriguing catalyst paths over the next yr in large cap pharma and trades ~15% below where it traded at the start of the COVID pandemic." The analyst added Pfizer has already presented "an impressive innovation framework" that has helped the company adapt to healthcare headwinds, which underpinned the bullish long-term view. "During the pandemic, Pfizer in collaboration with Biontech rolled out COVID vaccines in a historical timeframe. PFE YTD mountain Pfizer stock YTD — CNBC's Michael Bloom contributed to this report.

Persons: Jefferies, Akash Tewari, it's, Tewari, PFE, Biontech, Paxlovid, Michael Bloom Organizations: Pfizer, pharma

☆ Moderna reaffirms annual COVID vaccine sales forecast
▼ + stars: | 2023-10-16 | by ( ) www.reuters.com time to read: 1 min

Syringes with needles are seen in front of a displayed Moderna logo in this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsCompanies Moderna Inc FollowPfizer Inc FollowOct 16 (Reuters) - Moderna (MRNA.O) on Monday reaffirmed its forecast of $6 billion to $8 billion in COVID vaccine sales for the year, after rival Pfizer (PFE.N) slashed forecast for its vaccine last week. Moderna said it will have "improved visibility" about the expected U.S. market size for vaccines after observing trends through October 2023. Shares of Moderna were down about 4% in premarket trading. Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi MajumdarOur Standards: The Thomson Reuters Trust Principles.

Persons: Dado Ruvic, Bhanvi, Shilpi Majumdar Organizations: REUTERS, Moderna Inc, Pfizer, Moderna, Thomson Locations: Bengaluru

☆ Pfizer slashes revenue forecast on lower COVID sales, will cut costs
▼ + stars: | 2023-10-13 | by ( Michael Erman | ) www.reuters.com time to read: +3 min

Pfizer and rivals have begun selling an updated COVID vaccine for this fall. The drugmaker said it now expects 2023 revenue of between $58 billion and $61 billion, down from its prior forecast of $67 billion to $70 billion. It had previously expected Paxlovid revenue of about $8 billion for the year. Pfizer also cut full-year revenue expectations for the COVID vaccine by about $2 billion due to lower-than-expected vaccination rates. Pfizer said its non-COVID products remain on track to achieve 6% to 8% revenue growth year over year in 2023.

Persons: Albert Boura, Michael Erman, Sriparna Roy, Bill Berkrot, Rod Nickel Organizations: Pfizer, U.S ., Strategic, Thomson Locations: York, New Jersey, Bengaluru

☆ US FDA approves Pfizer's inflammatory bowel disease drug
▼ + stars: | 2023-10-13 | by ( ) www.reuters.com time to read: +1 min

REUTERS/Johanna Geron/File Photo Acquire Licensing RightsOct 13 (Reuters) - The U.S. Food and Drug Administration has approved Pfizer's (PFE.N) drug to treat adults with an inflammatory bowel disease called ulcerative colitis, the company said on Friday. The decision was based on data from a late-stage study that showed a reduction in disease symptoms for some patients who took the drug, when compared with the placebo. Globally, the market for inflammatory bowel diseases is about $20 billion, making it a lucrative target for drugmakers. Analysts last year estimated that peak sales for the Pfizer drug could top $3 billion a year. Reporting by Khushi Mandowara in Bengaluru; Editing by Arun Koyyur and Devika SyamnathOur Standards: The Thomson Reuters Trust Principles.

Persons: Johanna Geron, Velsipity, Bristol Myers, Khushi, Arun Koyyur Organizations: Pfizer, REUTERS, U.S . Food, Drug Administration, Arena Pharmaceuticals, Bristol, drugmakers, Thomson Locations: Puurs, Belgium, U.S, United States, Bengaluru

"I just want to say how deeply saddened that we all are about the recent horrific attacks on Israel ... He warned that the war in Ukraine, compounded by the attacks on Israel, could have "far-reaching impacts on energy and food markets, global trade, and geopolitical relationships." On Friday, Citigroup CEO Jane Fraser included Israel in her opening remarks on the bank's earnings call. "Once someone ventures into the space of, 'who is the perpetrator and who is the victim,' you enter into the exposure of social media disinformation and risk," Kotok said. Some large companies including Apple (AAPL.O) and Walmart (WMT.N) had yet to issue statements, while some prominent personalities including NBA star LeBron James have spoken out.

Persons: JPMorgan Chase, Jamie Dimon, Albert Bourla, Jefferies, Michael Bloomberg, Goldman Sachs, Jane Fraser, Israel, Fraser, Larry Fink, David Kotok, Cumberland, Kotok, Antonio Neri, Andy Jassy, Sundar Pichai, Satya Nadella, LeBron James, Gigi Hadid, Lananh Nguyen, Aditya Soni, Stephen Nellis, Siddharth Cavale, David Gaffen, Arriana, Sayantani Ghosh, David Gregorio Our Organizations: JPMorgan, Pfizer, UBS, New York City, Bloomberg, Delta Air Lines, Citigroup, BlackRock, Cumberland Advisors, Hewlett Packard Enterprise, Amazon, Meta, Union, Google, Microsoft, Apple, Walmart, NBA, Thomson Locations: Israel, Ukraine, New York, Florida, Bengaluru

☆ Over 7 million Americans have gotten updated COVID vaccines
▼ + stars: | 2023-10-12 | by ( Patrick Wingrove | ) www.reuters.com time to read: +2 min

Millions of doses of another updated COVID vaccine from Novavax (NVAX.O) have also been made available to Americans this week, according to the company. Last year's booster targeting the original virus and another variant was rolled out about 10 days earlier. By Sept. 28, 2022, almost 7.6 million Americans had received the updated shots. U.S. public health officials have been optimistic that Americans will get the new vaccines and have recommended that everyone ages 6 months and older receive one. About 17% of the U.S. population, or 56.5 million people, ultimately received last year's version of the vaccines.

Persons: Emily Elconin, Patrick Wingrove, Bill Berkrot Organizations: REUTERS, U.S . Department of Health, Human Services, Pfizer, Moderna, U.S . Centers, Disease Control, Thomson Locations: Waterford , Michigan, U.S, Moderna, Novavax

The trial for the Cantlay/Harper case, which was set to begin on Nov. 13, will now be dismissed, GSK said, adding it had also settled three remaining breast cancer cases in California related to the same drug. The latest settlements in California were related to cases due to go to trial in November, with a further set scheduled to begin in Delaware courts in January, GSK said. The company still faces about 79,000 cases related to Zantac in the United States, with 73,000 of them in Delaware. GSK did not admit any liability and said it would vigorously defend itself in any other Zantac cases. In June, GSK agreed to settle a similar lawsuit in California.

Persons: Harper, Brendan McDermid, Morgan, Jeffries, Zantac, Boehringer Ingelheim, Eva Mathews, Maggie Fick, Nivedita Bhattacharjee, Bernadette Baum, Louise Heavens, Emelia Organizations: pare, Citi, GSK, Reuters, REUTERS, Barclays, Pfizer, Sanofi, FDA, Thomson Locations: California, British, Delaware, United States, Arexvy, California . California, Bengaluru, London

REUTERS/Brendan McDermid/Illustration/File Photo Acquire Licensing RightsOct 11 (Reuters) - GSK (GSK.L) on Wednesday said it would confidentially settle another lawsuit in California alleging its discontinued heartburn drug Zantac caused cancer, as the British drugmaker sought to end costly litigation. The latest settlements in California related to cases due to go to trial in November, with a further set scheduled to begin in Delaware courts in January, GSK said. The company still faces about 79,000 cases related to Zantac in the United States, with 73,000 of them in Delaware. Late in June, the company agreed to settle a similar lawsuit with California resident James Goetz who alleged he developed bladder cancer after taking Zantac. The settlement could be read that GSK sees a risk that these Zantac cases are strong enough that the company might lose at trial, J.P Morgan added.

Persons: Brendan McDermid, Morgan, Harper, Zantac, Boehringer Ingelheim, James Goetz, J.P Morgan, Eva Mathews, Maggie Fick, Nivedita Bhattacharjee, Bernadette Baum Organizations: REUTERS, GSK, Citi, J.P, Pfizer, Sanofi, FDA, Thomson Locations: California, British, Delaware, United States, Bengaluru, London

Centerview Partners also advised Exxon, while Morgan Stanley and Bank of America secured advisory roles with Pioneer. A transaction of this size typically results in tens of millions of dollars worth of fees for advisory firms. The chairman of the firm, Tom Petrie, was a co-founder of Petrie Parkman and served a vice chairman at Bank of America before the current Petrie was created. Three of those - Andrew Rapp and Mike Bock in Denver, as well as Jon Hughes in Houston - have been with the firm since its days as Petrie Parkman. Reporting by Anirban Sen and David French in New York Editing by Nick ZieminskiOur Standards: The Thomson Reuters Trust Principles.

Persons: Lucas Jackson, Goldman Sachs, Morgan Stanley, Centerview, LSEG, Petrie Parkman, Merrill Lynch, Tom Petrie, Petrie, Andrew Rapp, Mike Bock, Jon Hughes, Anirban Sen, David French, Nick Zieminski Organizations: Exxon, New York Stock Exchange, REUTERS, Petrie Partners, Natural Resources, Exxon Mobil, Goldman, Citigroup Inc, Pioneer, Centerview Partners, Bank of America, Seagen Inc, Pfizer Inc, Guggenheim Securities, Co, U.S . Department of Energy, Thomson, & $ Locations: New York, Dealogic . Denver, Bank, Saudi Arabia, Alaska, Denver, Houston ., Houston

Search resuls for: "PFE"

25 mentions found